Identifying a predictive relationship between maximal flow rate and viscosity for subcutaneous administration of macromolecules with recombinant human hyaluronidase PH20 in a miniature pig model
Drug Deliv. 2023 Dec;30(1):2252999. doi: 10.1080/10717544.2023.2252999.ABSTRACTSubcutaneous (SC) infusion of large volumes at rapid flow rates has historically been limited by the glycosaminoglycan hyaluronan (HA), which forms a barrier to bulk fluid flow in the SC space. Recombinant human hyaluronidase PH20 (rHuPH20) depolymerizes HA, temporarily eliminating this barrier to rapid SC delivery of large volume co-administered therapeutics. Using a miniature pig model, in-line pressure and applied force to the delivery hardware were measured when subcutaneously infusing a representative macromolecule (human polyclonal immunog...
Source: Drug Delivery - September 13, 2023 Category: Drugs & Pharmacology Authors: Robert J Connor Renee Clift David W Kang Source Type: research
Advances in smart delivery of magnetic field-targeted drugs in cardiovascular diseases
Drug Deliv. 2023 Dec;30(1):2256495. doi: 10.1080/10717544.2023.2256495.ABSTRACTMagnetic Drug Targeting (MDT) is of particular interest to researchers because of its good loading efficiency, targeting accuracy, and versatile use in vivo. Cardiovascular Disease (CVD) is a global chronic disease with a high mortality rate, and the development of more precise and effective treatments is imminent. A growing number of studies have begun to explore the feasibility of MDT in CVD, but an up-to-date systematic summary is still lacking. This review discusses the current research status of MDT from guiding magnetic fields, magnetic na...
Source: Drug Delivery - September 13, 2023 Category: Drugs & Pharmacology Authors: Xinyu Wang Ruru Bai Source Type: research
Identifying a predictive relationship between maximal flow rate and viscosity for subcutaneous administration of macromolecules with recombinant human hyaluronidase PH20 in a miniature pig model
Drug Deliv. 2023 Dec;30(1):2252999. doi: 10.1080/10717544.2023.2252999.ABSTRACTSubcutaneous (SC) infusion of large volumes at rapid flow rates has historically been limited by the glycosaminoglycan hyaluronan (HA), which forms a barrier to bulk fluid flow in the SC space. Recombinant human hyaluronidase PH20 (rHuPH20) depolymerizes HA, temporarily eliminating this barrier to rapid SC delivery of large volume co-administered therapeutics. Using a miniature pig model, in-line pressure and applied force to the delivery hardware were measured when subcutaneously infusing a representative macromolecule (human polyclonal immunog...
Source: Drug Delivery - September 13, 2023 Category: Drugs & Pharmacology Authors: Robert J Connor Renee Clift David W Kang Source Type: research
Advances in smart delivery of magnetic field-targeted drugs in cardiovascular diseases
Drug Deliv. 2023 Dec;30(1):2256495. doi: 10.1080/10717544.2023.2256495.ABSTRACTMagnetic Drug Targeting (MDT) is of particular interest to researchers because of its good loading efficiency, targeting accuracy, and versatile use in vivo. Cardiovascular Disease (CVD) is a global chronic disease with a high mortality rate, and the development of more precise and effective treatments is imminent. A growing number of studies have begun to explore the feasibility of MDT in CVD, but an up-to-date systematic summary is still lacking. This review discusses the current research status of MDT from guiding magnetic fields, magnetic na...
Source: Drug Delivery - September 13, 2023 Category: Drugs & Pharmacology Authors: Xinyu Wang Ruru Bai Source Type: research
Identifying a predictive relationship between maximal flow rate and viscosity for subcutaneous administration of macromolecules with recombinant human hyaluronidase PH20 in a miniature pig model
Drug Deliv. 2023 Dec;30(1):2252999. doi: 10.1080/10717544.2023.2252999.ABSTRACTSubcutaneous (SC) infusion of large volumes at rapid flow rates has historically been limited by the glycosaminoglycan hyaluronan (HA), which forms a barrier to bulk fluid flow in the SC space. Recombinant human hyaluronidase PH20 (rHuPH20) depolymerizes HA, temporarily eliminating this barrier to rapid SC delivery of large volume co-administered therapeutics. Using a miniature pig model, in-line pressure and applied force to the delivery hardware were measured when subcutaneously infusing a representative macromolecule (human polyclonal immunog...
Source: Drug Delivery - September 13, 2023 Category: Drugs & Pharmacology Authors: Robert J Connor Renee Clift David W Kang Source Type: research
Advances in smart delivery of magnetic field-targeted drugs in cardiovascular diseases
Drug Deliv. 2023 Dec;30(1):2256495. doi: 10.1080/10717544.2023.2256495.ABSTRACTMagnetic Drug Targeting (MDT) is of particular interest to researchers because of its good loading efficiency, targeting accuracy, and versatile use in vivo. Cardiovascular Disease (CVD) is a global chronic disease with a high mortality rate, and the development of more precise and effective treatments is imminent. A growing number of studies have begun to explore the feasibility of MDT in CVD, but an up-to-date systematic summary is still lacking. This review discusses the current research status of MDT from guiding magnetic fields, magnetic na...
Source: Drug Delivery - September 13, 2023 Category: Drugs & Pharmacology Authors: Xinyu Wang Ruru Bai Source Type: research
Identifying a predictive relationship between maximal flow rate and viscosity for subcutaneous administration of macromolecules with recombinant human hyaluronidase PH20 in a miniature pig model
Drug Deliv. 2023 Dec;30(1):2252999. doi: 10.1080/10717544.2023.2252999.ABSTRACTSubcutaneous (SC) infusion of large volumes at rapid flow rates has historically been limited by the glycosaminoglycan hyaluronan (HA), which forms a barrier to bulk fluid flow in the SC space. Recombinant human hyaluronidase PH20 (rHuPH20) depolymerizes HA, temporarily eliminating this barrier to rapid SC delivery of large volume co-administered therapeutics. Using a miniature pig model, in-line pressure and applied force to the delivery hardware were measured when subcutaneously infusing a representative macromolecule (human polyclonal immunog...
Source: Drug Delivery - September 13, 2023 Category: Drugs & Pharmacology Authors: Robert J Connor Renee Clift David W Kang Source Type: research
Advances in smart delivery of magnetic field-targeted drugs in cardiovascular diseases
Drug Deliv. 2023 Dec;30(1):2256495. doi: 10.1080/10717544.2023.2256495.ABSTRACTMagnetic Drug Targeting (MDT) is of particular interest to researchers because of its good loading efficiency, targeting accuracy, and versatile use in vivo. Cardiovascular Disease (CVD) is a global chronic disease with a high mortality rate, and the development of more precise and effective treatments is imminent. A growing number of studies have begun to explore the feasibility of MDT in CVD, but an up-to-date systematic summary is still lacking. This review discusses the current research status of MDT from guiding magnetic fields, magnetic na...
Source: Drug Delivery - September 13, 2023 Category: Drugs & Pharmacology Authors: Xinyu Wang Ruru Bai Source Type: research
Identifying a predictive relationship between maximal flow rate and viscosity for subcutaneous administration of macromolecules with recombinant human hyaluronidase PH20 in a miniature pig model
Drug Deliv. 2023 Dec;30(1):2252999. doi: 10.1080/10717544.2023.2252999.ABSTRACTSubcutaneous (SC) infusion of large volumes at rapid flow rates has historically been limited by the glycosaminoglycan hyaluronan (HA), which forms a barrier to bulk fluid flow in the SC space. Recombinant human hyaluronidase PH20 (rHuPH20) depolymerizes HA, temporarily eliminating this barrier to rapid SC delivery of large volume co-administered therapeutics. Using a miniature pig model, in-line pressure and applied force to the delivery hardware were measured when subcutaneously infusing a representative macromolecule (human polyclonal immunog...
Source: Drug Delivery - September 13, 2023 Category: Drugs & Pharmacology Authors: Robert J Connor Renee Clift David W Kang Source Type: research
Advances in smart delivery of magnetic field-targeted drugs in cardiovascular diseases
Drug Deliv. 2023 Dec;30(1):2256495. doi: 10.1080/10717544.2023.2256495.ABSTRACTMagnetic Drug Targeting (MDT) is of particular interest to researchers because of its good loading efficiency, targeting accuracy, and versatile use in vivo. Cardiovascular Disease (CVD) is a global chronic disease with a high mortality rate, and the development of more precise and effective treatments is imminent. A growing number of studies have begun to explore the feasibility of MDT in CVD, but an up-to-date systematic summary is still lacking. This review discusses the current research status of MDT from guiding magnetic fields, magnetic na...
Source: Drug Delivery - September 13, 2023 Category: Drugs & Pharmacology Authors: Xinyu Wang Ruru Bai Source Type: research
Identifying a predictive relationship between maximal flow rate and viscosity for subcutaneous administration of macromolecules with recombinant human hyaluronidase PH20 in a miniature pig model
Drug Deliv. 2023 Dec;30(1):2252999. doi: 10.1080/10717544.2023.2252999.ABSTRACTSubcutaneous (SC) infusion of large volumes at rapid flow rates has historically been limited by the glycosaminoglycan hyaluronan (HA), which forms a barrier to bulk fluid flow in the SC space. Recombinant human hyaluronidase PH20 (rHuPH20) depolymerizes HA, temporarily eliminating this barrier to rapid SC delivery of large volume co-administered therapeutics. Using a miniature pig model, in-line pressure and applied force to the delivery hardware were measured when subcutaneously infusing a representative macromolecule (human polyclonal immunog...
Source: Drug Delivery - September 13, 2023 Category: Drugs & Pharmacology Authors: Robert J Connor Renee Clift David W Kang Source Type: research
Advances in smart delivery of magnetic field-targeted drugs in cardiovascular diseases
Drug Deliv. 2023 Dec;30(1):2256495. doi: 10.1080/10717544.2023.2256495.ABSTRACTMagnetic Drug Targeting (MDT) is of particular interest to researchers because of its good loading efficiency, targeting accuracy, and versatile use in vivo. Cardiovascular Disease (CVD) is a global chronic disease with a high mortality rate, and the development of more precise and effective treatments is imminent. A growing number of studies have begun to explore the feasibility of MDT in CVD, but an up-to-date systematic summary is still lacking. This review discusses the current research status of MDT from guiding magnetic fields, magnetic na...
Source: Drug Delivery - September 13, 2023 Category: Drugs & Pharmacology Authors: Xinyu Wang Ruru Bai Source Type: research
Identifying a predictive relationship between maximal flow rate and viscosity for subcutaneous administration of macromolecules with recombinant human hyaluronidase PH20 in a miniature pig model
Drug Deliv. 2023 Dec;30(1):2252999. doi: 10.1080/10717544.2023.2252999.ABSTRACTSubcutaneous (SC) infusion of large volumes at rapid flow rates has historically been limited by the glycosaminoglycan hyaluronan (HA), which forms a barrier to bulk fluid flow in the SC space. Recombinant human hyaluronidase PH20 (rHuPH20) depolymerizes HA, temporarily eliminating this barrier to rapid SC delivery of large volume co-administered therapeutics. Using a miniature pig model, in-line pressure and applied force to the delivery hardware were measured when subcutaneously infusing a representative macromolecule (human polyclonal immunog...
Source: Drug Delivery - September 13, 2023 Category: Drugs & Pharmacology Authors: Robert J Connor Renee Clift David W Kang Source Type: research
Advances in smart delivery of magnetic field-targeted drugs in cardiovascular diseases
Drug Deliv. 2023 Dec;30(1):2256495. doi: 10.1080/10717544.2023.2256495.ABSTRACTMagnetic Drug Targeting (MDT) is of particular interest to researchers because of its good loading efficiency, targeting accuracy, and versatile use in vivo. Cardiovascular Disease (CVD) is a global chronic disease with a high mortality rate, and the development of more precise and effective treatments is imminent. A growing number of studies have begun to explore the feasibility of MDT in CVD, but an up-to-date systematic summary is still lacking. This review discusses the current research status of MDT from guiding magnetic fields, magnetic na...
Source: Drug Delivery - September 13, 2023 Category: Drugs & Pharmacology Authors: Xinyu Wang Ruru Bai Source Type: research
Identifying a predictive relationship between maximal flow rate and viscosity for subcutaneous administration of macromolecules with recombinant human hyaluronidase PH20 in a miniature pig model
Drug Deliv. 2023 Dec;30(1):2252999. doi: 10.1080/10717544.2023.2252999.ABSTRACTSubcutaneous (SC) infusion of large volumes at rapid flow rates has historically been limited by the glycosaminoglycan hyaluronan (HA), which forms a barrier to bulk fluid flow in the SC space. Recombinant human hyaluronidase PH20 (rHuPH20) depolymerizes HA, temporarily eliminating this barrier to rapid SC delivery of large volume co-administered therapeutics. Using a miniature pig model, in-line pressure and applied force to the delivery hardware were measured when subcutaneously infusing a representative macromolecule (human polyclonal immunog...
Source: Drug Delivery - September 13, 2023 Category: Drugs & Pharmacology Authors: Robert J Connor Renee Clift David W Kang Source Type: research
